OrPro Therapeutics Receives $2.147M Therapeutic Development Funding from US Department of Defense for COVID-19 and Influenza

Journal Article Cites HemoVoid™ in Proteomic Study of Schizophrenia

Journal Article Describes HemogloBind™ To Reduce Analytical Interferences from Hemolysis